231 related articles for article (PubMed ID: 7585656)
1. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
Saffari B; Jones LA; el-Naggar A; Felix JC; George J; Press MF
Cancer Res; 1995 Dec; 55(23):5693-8. PubMed ID: 7585656
[TBL] [Abstract][Full Text] [Related]
2. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
3. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS
Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
5. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
Slomovitz BM; Broaddus RR; Burke TW; Sneige N; Soliman PT; Wu W; Sun CC; Munsell MF; Gershenson DM; Lu KH
J Clin Oncol; 2004 Aug; 22(15):3126-32. PubMed ID: 15284264
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
[TBL] [Abstract][Full Text] [Related]
7. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis.
Press MF; Pike MC; Hung G; Zhou JY; Ma Y; George J; Dietz-Band J; James W; Slamon DJ; Batsakis JG
Cancer Res; 1994 Nov; 54(21):5675-82. PubMed ID: 7522962
[TBL] [Abstract][Full Text] [Related]
8. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.
Morrison C; Zanagnolo V; Ramirez N; Cohn DE; Kelbick N; Copeland L; Maxwell GL; Fowler JM
J Clin Oncol; 2006 May; 24(15):2376-85. PubMed ID: 16710036
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
Persons DL; Borelli KA; Hsu PH
Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer.
Williams JA; Wang ZR; Parrish RS; Hazlett LJ; Smith ST; Young SR
Exp Mol Pathol; 1999 Dec; 67(3):135-43. PubMed ID: 10600396
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters.
Cianciulli AM; Guadagni F; Marzano R; Benevolo M; Merola R; Giannarelli D; Marandino F; Vocaturo G; Mariani L; Mottolese M
J Exp Clin Cancer Res; 2003 Jun; 22(2):265-71. PubMed ID: 12866577
[TBL] [Abstract][Full Text] [Related]
12. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
13. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
[TBL] [Abstract][Full Text] [Related]
14. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
[TBL] [Abstract][Full Text] [Related]
15. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
16. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
17. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
Grushko TA; Blackwood MA; Schumm PL; Hagos FG; Adeyanju MO; Feldman MD; Sanders MO; Weber BL; Olopade OI
Cancer Res; 2002 Mar; 62(5):1481-8. PubMed ID: 11888924
[TBL] [Abstract][Full Text] [Related]
18. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness.
Goebel SU; Iwamoto M; Raffeld M; Gibril F; Hou W; Serrano J; Jensen RT
Cancer Res; 2002 Jul; 62(13):3702-10. PubMed ID: 12097278
[TBL] [Abstract][Full Text] [Related]
19. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
Giltnane JM; Murren JR; Rimm DL; King BL
Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
[TBL] [Abstract][Full Text] [Related]
20. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers.
Bizari L; Borim AA; Leite KR; Gonçalves Fde T; Cury PM; Tajara EH; Silva AE
Cancer Genet Cytogenet; 2006 Feb; 165(1):41-50. PubMed ID: 16490596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
